ATE305303T1 - 6-substituierte pyridopyrimidine - Google Patents

6-substituierte pyridopyrimidine

Info

Publication number
ATE305303T1
ATE305303T1 AT02726103T AT02726103T ATE305303T1 AT E305303 T1 ATE305303 T1 AT E305303T1 AT 02726103 T AT02726103 T AT 02726103T AT 02726103 T AT02726103 T AT 02726103T AT E305303 T1 ATE305303 T1 AT E305303T1
Authority
AT
Austria
Prior art keywords
pyridopyrimidines
substituted
substituted pyridopyrimidines
Prior art date
Application number
AT02726103T
Other languages
English (en)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Christoph Martin Stahl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE305303T1 publication Critical patent/ATE305303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02726103T 2001-02-12 2002-02-04 6-substituierte pyridopyrimidine ATE305303T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Publications (1)

Publication Number Publication Date
ATE305303T1 true ATE305303T1 (de) 2005-10-15

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726103T ATE305303T1 (de) 2001-02-12 2002-02-04 6-substituierte pyridopyrimidine

Country Status (31)

Country Link
US (3) US6696566B2 (de)
EP (1) EP1361880B1 (de)
JP (1) JP4064818B2 (de)
KR (1) KR100639772B1 (de)
CN (1) CN100376571C (de)
AR (1) AR035854A1 (de)
AT (1) ATE305303T1 (de)
AU (1) AU2002256615B2 (de)
BR (1) BRPI0207172B8 (de)
CA (1) CA2434834C (de)
CZ (1) CZ20032416A3 (de)
DE (1) DE60206363T2 (de)
DK (1) DK1361880T3 (de)
ES (1) ES2249574T3 (de)
HR (1) HRP20030624B1 (de)
HU (1) HU229604B1 (de)
IL (2) IL156872A0 (de)
JO (1) JO2410B1 (de)
MA (1) MA26993A1 (de)
MX (1) MXPA03007166A (de)
MY (1) MY131518A (de)
NO (1) NO326133B1 (de)
NZ (1) NZ526961A (de)
PA (1) PA8539201A1 (de)
PE (1) PE20020976A1 (de)
PL (1) PL366918A1 (de)
RU (1) RU2269527C2 (de)
SK (1) SK11322003A3 (de)
WO (1) WO2002064594A2 (de)
YU (1) YU63703A (de)
ZA (1) ZA200305938B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
RU2310657C2 (ru) 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
ES2279361T3 (es) * 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (de) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidine als entzüngungshemmende mittel
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2006082492A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
JP5198256B2 (ja) * 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
MX2008014908A (es) * 2006-05-26 2009-05-13 Toyama Chemical Co Ltd Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
US8022085B2 (en) 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
CA2690327A1 (en) 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
US8367671B2 (en) 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EP2112150B1 (de) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Verbesserte Raf-Inhibitoren
CN102177161A (zh) * 2008-10-22 2011-09-07 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
CN102648200A (zh) 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN115105601A (zh) * 2016-06-08 2022-09-27 投资支持有限公司 用于治疗癌症的药物组合
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
PE20190421A1 (es) 2016-08-17 2019-03-19 Support Venture Gmbh Metodo para prevenir o tratar la perdida de la audicion
WO2018132550A1 (en) * 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
KR20190137854A (ko) * 2017-04-04 2019-12-11 스트리킨 아게 안과 질병의 예방 또는 치료 방법
AU2018325442B2 (en) * 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
CN120247910B (zh) * 2025-04-01 2026-05-05 赣南师范大学 一种杂环类化合物及其制备方法、应用和防治肿瘤的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
EP0278686A1 (de) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen davon
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
TW299333B (de) * 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
FI971953A7 (fi) * 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
IL131618A0 (en) 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7－三取代的－4－氨基吡啶并[2,3－d]嘧啶化合物
DE69939168D1 (de) 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
EP1078923B1 (de) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer

Also Published As

Publication number Publication date
US7169794B2 (en) 2007-01-30
HRP20030624B1 (en) 2007-03-31
MA26993A1 (fr) 2004-12-20
PE20020976A1 (es) 2002-10-29
HRP20030624A2 (en) 2005-06-30
CN1503672A (zh) 2004-06-09
HUP0303458A3 (en) 2012-12-28
DE60206363T2 (de) 2006-07-06
SK11322003A3 (en) 2004-10-05
JO2410B1 (en) 2007-06-17
IL156872A0 (en) 2004-02-08
PL366918A1 (en) 2005-02-07
US20070135458A1 (en) 2007-06-14
US6696566B2 (en) 2004-02-24
ES2249574T3 (es) 2006-04-01
EP1361880B1 (de) 2005-09-28
DK1361880T3 (da) 2006-01-23
HUP0303458A2 (hu) 2004-01-28
RU2269527C2 (ru) 2006-02-10
CZ20032416A3 (cs) 2004-07-14
JP4064818B2 (ja) 2008-03-19
MY131518A (en) 2007-08-30
KR20040018254A (ko) 2004-03-02
BRPI0207172B1 (pt) 2019-04-09
HU229604B1 (en) 2014-02-28
YU63703A (sh) 2006-05-25
NO326133B1 (no) 2008-10-06
CA2434834C (en) 2010-09-14
US20040116698A1 (en) 2004-06-17
BR0207172A (pt) 2004-03-30
BRPI0207172B8 (pt) 2021-05-25
CA2434834A1 (en) 2002-08-22
IL156872A (en) 2009-07-20
NO20033540D0 (no) 2003-08-11
RU2003125887A (ru) 2005-03-20
US20030171584A1 (en) 2003-09-11
AU2002256615B2 (en) 2007-09-13
MXPA03007166A (es) 2003-11-18
PA8539201A1 (es) 2004-08-31
HK1066170A1 (en) 2005-03-18
KR100639772B1 (ko) 2006-10-30
CN100376571C (zh) 2008-03-26
ZA200305938B (en) 2005-01-26
US7449581B2 (en) 2008-11-11
EP1361880A2 (de) 2003-11-19
WO2002064594A3 (en) 2003-01-09
WO2002064594A2 (en) 2002-08-22
NZ526961A (en) 2005-03-24
JP2004525896A (ja) 2004-08-26
AR035854A1 (es) 2004-07-21
DE60206363D1 (de) 2006-02-09
NO20033540L (no) 2003-08-11

Similar Documents

Publication Publication Date Title
DE60206363D1 (de) 6-substituierte pyridopyrimidine
NO20042755L (no) Amidsubstituerte imidazopyridiner
NO20035476D0 (no) Azaindoler
NO20032453L (no) Substituerte imidazopyridiner
HUS1500055I1 (hu) HIV-gátló pirimidinszármazékok
CY2014018I1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
PT1257276E (pt) Derivados de azaindole antivirais
DE50202178D1 (de) Neue sulfonat-substituierte pyrazolopyridinderivate
NO20042742L (no) Pyrimidinforbindelser
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE50208287D1 (de) Bicyclische n-arylamide
NO20033898L (no) Dimeriske isoflavoner
MXPA03007623A (es) Derivado de piridopirimidina o naftiridina.
DE60238924D1 (de) Abwälzfräser
FI20010668L (fi) Paikannuslaite
DE60211691D1 (de) Nietvorrichtung
ITMO20010040A0 (it) Mezzi per il riscaldamento di ambienti
ITMO20010041A0 (it) Mezzi per il riscaldamento di ambienti
SE0101050D0 (sv) Konvektor
NO20015976D0 (no) Solcelle
FIU20010005U0 (fi) Liesi
SE0103603D0 (sv) Uppsamlingskärl
SK3012U (sk) Agroturistický povoz
SE0103232D0 (sv) Vagn
FI5386U1 (fi) Jyrsin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1361880

Country of ref document: EP